(Q45297326)

English

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

scientific article published on 2 September 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

phase III clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

Eugene R Bleecker

1

object named as

Eugene R Bleecker

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

J Mark FitzGerald

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Pascal Chanez

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Alberto Papi

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Steven F Weinstein

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Peter Barker

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Stephanie Sproule

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Geoffrey Gilmartin

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Magnus Aurivillius

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Viktoria Werkström

10

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Mitchell Goldman

11

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

SIROCCO study investigators

12

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

2 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

388

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

10056

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

2115-2127

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Global asthma prevalence in adults: findings from the cross-sectional world health survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Asthma: still a promising future?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for death in patients with severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Direct health care costs associated with asthma in British Columbia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic burden of asthma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Tissue and BAL based biomarkers in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of loss of asthma control induced by corticosteroid withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab: a unique IL-5 inhibitor for severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reductions in eosinophil biomarkers by benralizumab in patients with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement properties and interpretation of three shortened versions of the asthma control questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

General considerations for lung function testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab treatment in patients with severe eosinophilic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931324-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)31324-1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45297326&oldid=2074108990"